Join to View Full Profile
1221 Madison StSeattle, WA 98104
Phone+1 206-386-2323
Fax+1 206-386-2729
Dr. Ellis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1988 - 1991
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
Johns Hopkins University School of MedicineClass of 1985
Certifications & Licensure
WA State Medical License 1991 - 2027
IL State Medical License 1985 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Publications & Presentations
PubMed
- 4 citationsRace, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien
JAMA Network Open. 2023-12-01 - 11 citationsSafety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf
NPJ Breast Cancer. 2022-12-01 - 40 citationsNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer
Nature Communications. 2021-11-05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
